Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience

Bella Halim, Mary B. Abraham, Georgina Manos, Arcelia Arrieta, Zheng Dai, Sara Vogrin, Jean Lu, Richard MacIsaac, Elif I. Ekinci, Elizabeth A. Davis, Alicia Jenkins, John Shin, Robert A. Vigersky, Timothy W. Jones, David O’Neal

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To assess the real-world performance of MiniMed™ 780G for Australians with type 1 diabetes (T1D) following advanced hybrid closed loop (AHCL) activation and to evaluate the effect of changing from MiniMed 670/770G to 780G. Methods: We analyzed deidentified Carelink™ continuous glucose monitoring (CGM) data from Australian users from January 2020 to December 2022, including the proportion attaining three major consensus targets: Glucose management indicator (GMI <7.0%), time in range (TIR 70–180 mg/dL >70%), and time below range (TBR 70 mg/dL <4%). Results: Comparing 670/770G users (n = 5676) for mean – standard deviation 364 – 244 days with 780G users (n = 3566) for 146 – 145 days, the latter achieved a higher TIR (72.6% – 10.6% vs. 67.3% – 11.4%; P < 0.001), lower time above range (TAR) (25.5% – 10.9% vs. 30.6% – 11.7%; P < 0.001), and lower GMI (6.9% – 0.4% vs. 7.2% – 0.4%; P < 0.001) without compromising TBR (1.9% – 1.8% vs. 2.0% – 1.8%; P = 0.0015). Of 1051 670/770G users transitioning to 780G, TIR increased (70.0% – 10.7% to 74.0% – 10.2%; P < 0.001), TAR decreased (28.1% – 10.9% to 24.0% – 10.7%; P < 0.001), and TBR was unchanged. The percentage of users attaining all three CGM targets was higher in 780G users (50.1% vs. 29.5%; P < 0.001). CGM metrics were stable at 12 months post-transition. Conclusion: Real-world data from Australia shows that a higher proportion of MiniMed 780G users meet clinical targets for CGM consensus metrics compared to MiniMed 670/770G users and glucose control was sustained over 12 months.

Original languageEnglish
Pages (from-to)190-197
Number of pages8
JournalDiabetes Technology and Therapeutics
Volume26
Issue number3
DOIs
Publication statusPublished - 1 Feb 2024

Fingerprint

Dive into the research topics of 'Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience'. Together they form a unique fingerprint.

Cite this